Navigation Links
Darvone-Darvocet Failure to Warn Claims Reinstated against Generic Drug Maker Wright & Schulte LLC Report
Date:3/15/2013

Dayton, OH (PRWEB) March 15, 2013

Wright & Schulte LLC, an experienced drug injury law firm, reports that Judge Reeves reinstated failure to warn claims against aaiPharma after dismissing them last March. Judge Reeves centered his decision on a controversial 2011 ‘preemptive’ ruling by the U.S. Supreme Court that generic drug manufacturers are protected from failure to warn lawsuits because they are federally required to carry the same warning labels as their brand name counterparts. This High Court ruling allows generic drug manufacturers to avoid liability for dangerous side effects, even if the generic manufacturer knows about the dangers.

Judge Reeves also decided that his interpretation of the High Court ruling barred the plaintiffs charges of breach of implied warranty, negligent marketing, defective design, strict liability and negligent design as well, writing in his decision that generic drug makers have a ‘federal duty of sameness’ that requires generic drugs to made the same as the brand name version, which prevents them from being responsible for those charges. Judge Reeves made his ruling March 1, 2013, after the plaintiff was able to show that he consumed Darvocet while it was being manufactured by aaiPharma. (Darvocet, Darvon and Propoxyphene. Products Liability Litigation – MDL 2226)

Darvon Darvocet Multidistrict Litigation
In November 2010 the Propoxyphene painkillers Darvon and Darvocet and their generic counterparts were pulled from the market after studies found that when taken at normal dosages, the drugs were causing serious side effects in healthy people. These side effects include heart arrhythmia, heart attack and sudden death. (http://www.citizen.org/Document.Doc?id=29)

Hundreds of federally filed Darvon and Darvocet injury lawsuits were consolidated by the U.S. Judicial Panel for Multidistrict Litigation in June 2012 to the U.S. District Court for the Eastern District of Kentucky under Judge Reeves. Wright & Schulte LLC partner Richard Schulte is serving as Co-Lead Council in the MDL.

Darvocet Darvon Side Effects
The opioid Propoxyphene is sold as Darvon or when combined with acetaminophen as Darvocet. It first hit the market in 1957 and became a widely prescribed painkiller. While the drugs had been pulled from the European market in 2009, the U.S. Food and Drug Administration only required a stronger warning label. In 2010, with some 10 million users in the U.S. alone, the government agency issued a ban on the drugs after it found that recommended dosages given to healthy individuals increased the risks of:

  •      Suicide
  •     Overdose
  •     Heart attack
  •     Heart arrhythmia
  •     Sudden death

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced drug injury law firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’ve been injured due to a harmful drug side effect, we urge you to contact Wright & Schulte LLC today through yourlegalhelp.com, or call 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795

Read the full story at http://www.prweb.com/releases/2013/3/prweb10521123.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Blood Test Plus Targeted Care May Stop Heart Failure Before It Starts
2. A Cheap, Old Heart Drug May Help Elderly Heart Failure Patients
3. Viagra, Aliskiren Not Helpful for Heart Failure After All: Studies
4. Common erectile dysfunction drug not helpful for heart failure patients, study finds
5. Certain Diabetes Medications May Lower Heart Failure Risk
6. Study: Diabetic medication may protect patients from developing heart failure
7. Researchers develop new tool to eliminate 30-day hospital readmissions in heart failure patients
8. Black Breast Cancer Survivors Face Higher Heart Failure Risk: Study
9. African-American breast cancer survivors face higher risk of heart failure
10. Electronic discharge tool reduces hospital readmissions in heart failure patients
11. Insomnia Might Boost Heart Failure Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated ... regulations. This is the first time that Coolsculpting is being used for for ... six months to ensure they meet the prescribed body-fat standard, measured by the circumference-based ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... trusted name in the pharmaceutical, medical and food industries. Aside from its GMP ... certification (SIC), providing proof of successfully certified products, services and staff. , Validation ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways ... and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. ... say grilling is their favorite way to cook a hot dog, far outpacing other ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... May 26, 2016 A key ... is the emergence of new treatments. Cardax, a development ... osteoarthritis treatment. The therapy is expected to fulfil large ... UK is conducting studies to develop new treatments for ... the genes involved in osteoarthritis are being investigated, and ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
Breaking Medicine Technology: